Researchers from Tango Therapeutics Inc. presented preclinical efficacy data on TNG-260, an inhibitor of the co-repressor of repressor element-1 silencing transcription (CoREST) deacetylase complex, designed to treat immunotherapy-resistant STK11-mutant tumors.
In a deal worth up to $840 million, Third Arc Bio Inc. is licensing Adagene Inc.’s Safebody technology platform to generate two masked CD3 T-cell engagers against unique tumor associated antigens.
Fifteen years since the first patient was treated, and after being ditched by two companies, the EMA is recommending approval of Waskyra (etuvetidigene autotemcel), the first gene therapy for treating Wiskott-Aldrich syndrome.
Novartis AG has described peptide-drug conjugates comprising cyclic peptides targeting HER2 (erbB2) covalently linked to a radiolabeled metal chelator through a linker reported to be useful for diagnosis and treatment of cancer.
Nanjing Zaiming Pharmaceutical Co. Ltd. has synthesized Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Shouyao Holdings (Beijing) Co. Ltd. has disclosed mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis, multiple sclerosis, psoriasis, Sjögren’s syndrome, systemic lupus erythematosus, erythema and vasculitis.
During the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scientists from Plexium Inc. presented the identification of a new class of potent, selective, cereblon (CRBN)-based molecular glue degraders of CDK2 using its proprietary monovalent degrader platform.
At the recent AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers from Aurigene Oncology Ltd. presented the discovery and clinical characterization of novel macrocyclic KIF18A inhibitors.
Researchers from the US National Institutes of Health (NIH) and Marengo Therapeutics Inc. previously developed a first-in-class, bifunctional therapeutic molecule (STAR-0602) that selectively activates V β6 and V β10 T-cell receptor-expressing T cells and boosts antitumor responses in human ex vivo tumor models.
RSS
